Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) director Laura Brege sold common stock totaling approximately $1.33 million on November 11, 2026, according to a recent disclosure. The transactions followed the exercise of stock options for shares valued at about $236,730.
Brege sold a total of 14,167 shares of Mirum Pharmaceuticals common stock. One block of 10,907 shares was sold at a weighted average price of $94.05, with individual prices ranging from $93.63 to $94.61. An additional 3,260 shares were sold at a weighted average price of $94.74, with prices ranging from $94.635 to $94.91.
Prior to these sales, Brege acquired 14,167 shares of common stock by exercising stock options at a price of $16.71 per share. These options were fully vested. Following these transactions, Brege directly holds 15,703 shares of Mirum Pharmaceuticals common stock.
The insider sale comes as the stock trades at $93.99, near the transaction prices. The company’s shares have delivered a strong 31.6% return over the past year, though analysis suggests the stock is slightly overvalued at current levels.
In other recent news, Mirum Pharmaceuticals reported third-quarter 2026 net product sales of $185.7 million, marking a 40% increase year-over-year and a 5% increase quarter-over-quarter. This revenue figure surpassed the consensus estimate of $178.1 million, showcasing strong commercial demand across its rare-disease portfolio. Despite the revenue success, the company posted an EPS of -$0.87, which was below the analyst estimate of -$0.49. Additionally, Mirum raised its 2026 sales outlook, reflecting confidence in its pipeline progress.
H.C. Wainwright reiterated a Buy rating on Mirum, maintaining a price target of $202 following positive Phase 3 trial results for its drug brelovitug. The trial showed significant virologic response and alanine aminotransferase normalization in patients with chronic hepatitis delta virus. Raymond James also increased its price target for Mirum to $189, citing continued commercial strength and growth in adult PFIC patients treated with Livmarli. Meanwhile, Citizens raised its price target to $167, highlighting Livmarli’s continued topline growth and the company’s diversified pipeline across late-stage opportunities. These developments underscore the positive sentiment among analysts regarding Mirum’s future prospects.